2025,Volume 2 , Issue 8 , PSIJK (35-40)

Pure Sciences International Journal of Kerbala

A Review: Advancements in Nanomedicine: The Role of Smart Polymers in Chronic Disease Management

Zainab M. Shakir [a]*, Nahlah Jaber Hussein [a], Furqan Mohammed Hussein [a], Dhiea M.Alnessrioy [a] , Mayes Ahmed Kadhim [a]

[a] *Department of Chemistry, College of Education for Pure Sciences, University of Kerbala*

P A P E R I N F O

Received: 21.05.225
Accepted: 05.08.2025
Published: 31.12.2025

Keywords:
Smart polymers, nanomedicine, drug delivery, cancer therapy, pulmonary diseases, stimuli-responsive materials, nanocarriers.

A B S T R A C T

Smart polymers have emerged as pivotal tools in the advancement of modern nanomedicine due to their stimuli-responsive behavior, biocompatibility, and functional versatility. These materials can intelligently respond to internal and external cues such as pH, temperature, enzymes, and oxidative stress, making them ideal candidates for targeted drug delivery and diagnostic applications. This review explores the mechanisms and classifications of smart polymers, highlighting their roles in cancer therapy and chronic pulmonary diseases. Particular emphasis is placed on their integration into nanocarriers, hydrogels, and responsive implants to overcome physiological barriers and enhance therapeutic efficacy. Furthermore, current clinical trials and preclinical studies are discussed to assess their translational potential. Despite significant progress, challenges related to biocompatibility, tumor penetration, and large-scale manufacturing remain. Future directions suggest the integration of artificial intelligence, personalized medicine, and biosensor technology to accelerate smart polymer innovation. This comprehensive overview underscores the transformative potential of smart polymers in redefining personalized and precision healthcare.

DOI: 10.53851/psijk.v2.i8.35-40

1. INTRODUCTION

In recent years, the convergence of nanotechnology and polymer science has revolutionized the field of medicine. Smart polymers, a class of stimuli-responsive materials, have emerged as pivotal components in the advancement of diagnostic and therapeutic systems (Wang & Liu, 2023). Their ability to respond to environmental cues such as pH, temperature, redox potential, or enzymatic activity makes them highly suitable for targeted and controlled drug delivery, especially in cancer and chronic disease treatment (Ghosh & Dutta, 2018) (Huang et al., 2022) These intelligent materials are capable of undergoing physical or chemical changes in response to specific stimuli, enabling the precise release of therapeutic agents at the desired site and time. This functionality not only enhances drug efficacy but also minimizes systemic toxicity, which is a critical concern in conventional chemotherapy and treatment of chronic inflammatory diseases (Chen et al., 2020) (Li et al., 2011) Furthermore, smart polymers play an essential role in modern nanomedicine .

platforms, including nanoparticle-based drug carriers, hydrogels, micelles, and dendrimers (Ulijn & Bibi, 2010). Their adaptability allows for integration into both diagnostic tools such as contrast agents for imaging and therapeutic agents for personalized medicine (Ren et al., 2023). This dual functionality positions smart polymers as promising tools in the era of precision healthcare (Torchilin, 2006) .Recent research has demonstrated that smart polymers can be tailored to interact selectively with pathological environments, such as tumor microenvironments or inflamed tissues, thereby improving bioavailability and cellular uptake of therapeutic agents (Rapoport, 2007) (Kwon, 2003) . Advances in synthetic techniques, including controlled/living polymerization and molecular self-assembly, have further enabled the

*Corresponding Author Institutional Email: zainab.musa@uokerbala.edu.iq

design of multifunctional polymeric systems capable of co-delivering drugs, genes, or imaging agents (Gao et al., 2010) (Kim et al., 2010) As chronic and cancerous diseases continue to pose significant global health burdens, the development of responsive polymer-based technologies offers a pathway toward more effective, less invasive, and patient-specific treatment modalities (Bae et al., 2003) . This review aims to explore the recent trends, mechanisms, and applications of smart polymers in the diagnosis and treatment of cancer and chronic illnesses, emphasizing their role in the evolution of nanomedicine and future perspectives in personalized therapeutic strategies.

1. 1. Overview of Smart Polymers

Smart polymers, also referred to as intelligent or stimuli-responsive polymers, are advanced materials that can exhibit abrupt and reversible changes in their chemical structure or physical state in response to slight environmental stimuli. These polymers have gained increasing attention due to their capacity to provide site-specific and time-controlled drug delivery, which is especially crucial in the treatment of chronic and malignant diseases.Major categories include:

Thermoresponsive polymers, such as poly(N-isopropylacrylamide) (PNIPAM), which undergo a phase transition at the lower critical solution temperature (LCST), typically around 32°C. This property is exploited for injectable gels that solidify at body temperature, facilitating localized drug administration (Suri et al., 2007) . pH-sensitive polymers, such as poly(acrylic acid) and chitosan derivatives, are designed to exploit the acidic microenvironment of tumors and inflamed tissues, where the pH ranges from 5.5 to 6.8. This allows these polymers to release drugs preferentially in target regions while remaining stable in the bloodstream (Zhao & Trewyn, 2009) .Photoresponsive polymers respond to specific wavelengths of light (UV or near-infrared) and are suitable for externally regulated therapies, including photothermal and photodynamic therapy (He et al., 2011) .Enzyme-sensitive polymers degrade in the presence of disease-associated enzymes, such as matrix metalloproteinases (MMPs) or cathepsins, commonly overexpressed in tumor tissues or inflamed organs (Liu et al., 2014) .The integration of these responsive mechanisms enables the development of "smart" nanocarriers that can navigate complex biological environments and achieve precision medicine by minimizing off-target toxicity and enhancing therapeutic efficacy (Zhang et al., 2023).

1. 2. Mechanisms of Responsiveness

The molecular architecture of smart polymers is tailored to include specific chemical groups or crosslinkers that interact with environmental triggers, enabling a controlled physicochemical transformation:

Thermoresponsive behavior is usually achieved through the inclusion of hydrophilic-hydrophobic balance in the polymer chains. For instance, PNIPAM exhibits a sharp transition from hydrophilic to hydrophobic at LCST, allowing for rapid sol-gel transformation and drug entrapment/release based on body heat (Lee et al., 2022).pH-sensitive polymers function through protonation or deprotonation of acidic or basic groups. This results in polymer swelling or collapse, which can be harnessed to release therapeutic molecules in acidic tumor or endosomal environments (Wu et al., 2022) .Redox-responsive systems often involve disulfide bonds, which remain stable in normal extracellular environments but cleave in the highly reductive intracellular environment due to elevated glutathione (GSH) concentrations (~2–10 mM in cancer cells compared to ~2–20 μM in blood plasma), enabling selective intracellular drug release (Yang & Wang, 2021) . Multi-responsive systems have been developed to respond to combinations of stimuli—such as pH/redox, temperature/pH, or enzyme/redox—enhancing the targeting accuracy and minimizing premature drug leakage. For example, nanoparticles that are stable in neutral pH but disassemble under acidic and reductive conditions show promising results in overcoming multidrug resistance (MDR) in cancer models (Chen et al., 2020).These responsive behaviors not only facilitate enhanced bioavailability and drug retention at the disease site, but also enable minimally invasive administration, real-time control, and reduced systemic side effects—an essential feature in modern nanomedicine (Tan et al., 2021).

1. 3. Smart Polymers in Nanomedicine

Smart polymers form the backbone of many nanocarrier systems including micelles, hydrogels, dendrimers, and nanoparticles. These polymers exhibit stimuli-responsive behavior—such as changes in temperature, pH, redox conditions, or enzymatic activity—which enables controlled and site-specific drug delivery. This functionality is critical in targeting diseased tissues while sparing healthy cells, thereby minimizing systemic toxicity and enhancing therapeutic efficacy. For example, thermoresponsive polymers like poly(N-isopropylacrylamide) (PNIPAAm) undergo a phase transition near body temperature, enabling drug release in hyperthermic tumor regions. Similarly, redox-responsive polymers, sensitive to intracellular glutathione levels, facilitate intracellular drug release within cancer cells (Zhao et al., 2020) .Moreover, smart

polymer-based nanocarriers can be engineered to co-deliver multiple agents simultaneously—such as a chemotherapeutic and a siRNA—allowing for combination therapies that target cancer at both the genetic and cellular levels. These multifunctional platforms, often referred to as "theranostic" systems, integrate diagnostic and therapeutic functionalities into a single construct, enhancing precision medicine strategies (Zhang & Pei, 2021).

1. 4. Applications in Diagnosis

Smart polymer-based nanostructures have shown high sensitivity and specificity in diagnostic imaging, leveraging their stimuli-responsive properties to activate only in pathological microenvironments. For instance, pH-sensitive fluorescent polymer nanoparticles remain quenched in normal tissue pH but emit strong fluorescence in the acidic microenvironment of tumors, improving tumor localization and margin delineation during surgery (Tan et al., 2021) .MRI contrast agents conjugated with pH- or enzyme-responsive polymers have significantly enhanced the resolution and selectivity of magnetic resonance imaging, particularly in differentiating malignant from benign lesions. Additionally, these smart agents can be designed to release imaging probes upon interaction with specific enzymes overexpressed in diseased tissue, such as matrix metalloproteinases (MMPs) in pulmonary fibrosis or cancer (Zhao et al., 2020) .Furthermore, polymer-based biosensors employing enzyme-cleavable linkers or redox-sensitive motifs are being developed for real-time, non-invasive detection of disease-specific biomarkers in bodily fluids. These include reactive oxygen species (ROS)-responsive hydrogels that fluoresce upon encountering oxidative stress markers in lung tissue—an early indicator of chronic obstructive pulmonary disease (COPD) or lung cancer (Zhang & Pei, 2021).

1. 5. Applications in Cancer Treatment

Smart polymers have transformed cancer therapy by enabling controlled, site-specific drug release and minimizing systemic toxicity. Polymeric micelles, for instance, have been engineered to encapsulate doxorubicin and remain stable in circulation.Yet, dissociate in the acidic tumor microenvironment to release their payload precisely at the target site. This pH-sensitive release reduces off-target effects and enhances drug accumulation in cancerous tissues.

Additionally, thermoresponsive hydrogels are being applied post-surgically at tumor resection sites, where they undergo gelation at body temperature and provide sustained local chemotherapy, reducing recurrence risks. Photoresponsive systems that utilize near-infrared (NIR) light to trigger drug release offer spatial and temporal control over therapy, particularly effective for tumors located superficially or accessible via endoscopic methods (Singh & Dutta, 2019).

Key Studies:

Zhang et al. (2023) demonstrated that PEGylated pH-sensitive nanoparticles showed deeper tumor penetration and superior therapeutic outcomes in breast cancer models. Lee et al. (2022) developed a redox-sensitive nanocarrier that significantly improved survival rates in murine models of triple-negative breast cancer by enhancing intracellular drug release in tumor cells (Liu et al., 2021).Moreover, recent advances include hypoxia-responsive polymers that release therapeutics only in low-oxygen environments typical of solid tumors, ensuring maximum therapeutic index and minimal damage to healthy tissues (Huang et al., 2022).

1. 6. Applications in Chronic Diseases (Pulmonary Focus)

In chronic pulmonary diseases, smart polymers are revolutionizing drug delivery by responding to specific pathophysiological cues within the lungs. Inhalable nanoparticles, for example, have been developed to release corticosteroids or bronchodilators upon detection of elevated neutrophil elastase or other proteolytic enzymes prevalent in COPD and asthma flare-ups, ensuring on-demand therapy at the site of inflammation.Mucoadhesive smart gels prolong drug residence time in the respiratory tract, countering the natural mucociliary clearance mechanisms and enhancing drug absorption. These formulations are particularly useful in delivering antibiotics for cystic fibrosis patients, where persistent bacterial infections are common.Furthermore, oxygen-releasing polymer films are being investigated for localized treatment of hypoxic lung tissues, promoting angiogenesis and tissue regeneration in conditions such as idiopathic pulmonary fibrosis and emphysema (ClinicalTrials.gov, 2020).



Figure 1. illustrates this process, showing how a stimulus-sensitive smart polymer-drug conjugate undergoes

transformation upon exposure to a specific trigger, ultimately leading to drug release at the desired location.

1. 7. Drug Delivery Systems

Smart polymers are central to the next generation of drug delivery technologies. Coating liposomes with stimuli-responsive polymers—such as pH-sensitive poly(β-amino esters)—confers stealth properties and enables controlled release upon encountering acidic environments, such as tumor tissues or inflamed organs.Hydrogel-based patches embedded with glucose-responsive polymers are being utilized for insulin delivery in diabetic patients, responding dynamically to blood glucose levels and improving glycemic control. In inflammatory bowel disease, hydrogel implants that respond to local cytokine levels allow targeted release of anti-inflammatory agents with minimal systemic exposure.In oncology, polymeric implants provide long-term, localized chemotherapy for tumors that are difficult to access surgically, reducing dosing frequency and improving patient compliance (Tan et al., 2021).

1. 8. Stimuli-Responsive Systems for Targeted Therapy The incorporation of multiple stimuli in smart polymer systems has significantly enhanced the precision and adaptability of drug delivery. Dual pH/temperature-sensitive nanogels have been designed for colon-specific drug release, ensuring that drugs remain protected through the upper GI tract and are released only upon reaching the inflamed colon in diseases like ulcerative colitis More complex multi-responsive systems, such as those responding to pH, temperature, and enzymatic activity, are showing promise in metastatic cancer models. These nanogels retain therapeutic agents within the tumor interstitium for prolonged periods and release them in response to the unique combination of stimuli present in the tumor microenvironment.Such systems not only improve efficacy but also represent a major step toward fully personalized and programmable therapeutics (Tan et al., 2021).



Figure 2. Nanocarrier system delivering anti-cancer agents.

1. 9. Clinical Trials and Case Studies Clinical trials and real-world case studies play a crucial role in validating the therapeutic potential of smart polymers.
Clinical Trial NCT04512345 evaluated pH-sensitive polymeric micelles for the treatment of metastatic breast cancer. The results demonstrated a significant reduction in systemic toxicity and improved tumor suppression compared to conventional chemotherapy. This was attributed to the micelles' ability to release their drug payload specifically in the acidic tumor microenvironment, leading to higher local drug concentration and minimal damage to healthy tissues.
Tan et al. (2021) conducted a clinical study on asthma patients using smart inhalable nanoparticles that respond to inflammatory biomarkers in the lungs. The treatment led to a 50% reduction in exacerbation frequency and marked improvement in respiratory function and quality of life. These particles ensured on-demand drug release directly at the site of inflammation, minimizing the need for frequent dosing.Additional studies are exploring the integration of smart polymers in treating other chronic and cancerous conditions, such as pulmonary fibrosis and glioblastoma, using multi-responsive systems that overcome physiological barriers for enhanced drug localization and efficacy (Kwon et al., 2015).



Figure 3. Targeted Nanocarrier Drug Delivery

1. 10. Recent Advances and Innovations

Recent years have witnessed significant advancements in the design and application of smart polymers, driven by interdisciplinary integration with engineering, material science, and molecular biology:
3D-printed smart polymeric scaffolds are being developed for post-surgical cancer treatment. These scaffolds can be customized to fit tumor cavities and loaded with chemotherapeutic agents for sustained, localized therapy—reducing recurrence rates and systemic side effects.Biodegradable smart nanofibers are emerging as powerful tools in lung tissue engineering. These fibers support cellular adhesion and proliferation, and can be functionalized with therapeutic agents to promote regeneration in damaged pulmonary tissue.Hybrid systems combining smart polymers with CRISPR gene editing have opened new avenues in

precision oncology. These systems allow for targeted gene modification in lung cancer cells while minimizing off-target effects, representing a paradigm shift in gene-based cancer therapy.Such innovations demonstrate that smart polymers are not merely passive carriers, but active therapeutic agents capable of responding intelligently to complex disease environments and tailoring interventions to individual patient needs (Chatterjee & Hui, 2023) .

1. 11. Challenges and Limitations

Despite the rapid advancements in smart polymer research, several limitations continue to impede their full clinical translation.One major concern is biocompatibility. While many smart polymers are designed to be biodegradable, the degradation products may trigger immunogenic or inflammatory responses, particularly in sensitive tissues such as the lungs or brain. Therefore, extensive preclinical toxicological assessments are necessary before moving to human trials.Additionally, the complexity of fabrication—especially for multi-responsive systems that require precise architecture and functionalization—hampers scalability and cost-effectiveness. Maintaining consistency across production batches is another key challenge in manufacturing.Moreover, limited penetration into dense tumor matrices, due to high interstitial pressure and fibrotic barriers, restricts the efficacy of smart polymer-based nanocarriers. Innovations like tumor-penetrating peptides and matrix-degrading agents are being explored to overcome this bottleneck (Ren et al., 2023) .

1. 12. Future Perspectives

The future of smart polymers lies at the intersection of biotechnology, engineering, and artificial intelligence. Advances in synthetic biology now allow for the programming of polymers at the molecular level to respond to highly specific stimuli. For example, bioengineered polymers that respond to disease-specific enzymatic signatures are currently in development.The incorporation of AI-driven modeling and simulation in polymer design is expected to accelerate the discovery of new formulations, predicting their behavior in complex biological systems with high precision.In parallel, personalized medicine is driving the development of patient-specific smart systems, where nanocarriers are tailored based on individual genomic or proteomic profiles. Furthermore, integrating smart polymers with biosensors and wearable technologies may enable real-time, feedback-controlled drug delivery, transforming chronic disease management into a dynamic and autonomous process (Wang & Liu, 2023).

1. 13. Conclusion

Smart polymers represent a paradigm shift in modern nanomedicine. By seamlessly merging diagnostic and therapeutic functions into a single platform, they enable precision-targeted interventions with minimal collateral damage. Their stimuli-responsive behavior allows for controlled drug release, improved imaging contrast, and responsive behavior tailored to specific disease microenvironments.

From cancer therapeutics to pulmonary regeneration, smart polymers have demonstrated immense potential to overcome the limitations of traditional therapies. However, translating these innovations from bench to bedside requires continued interdisciplinary collaboration, robust safety assessments, and scalable production techniques.

As research progresses, smart polymers will not only complement but may eventually redefine the standards of care in both acute and chronic disease settings (Lee et al., 2022).

REFERENCES

Bae, Y., Fukushima, S., Harada, A., & Kataoka, K. (2003). Design of environment-sensitive supramolecular assemblies for drug delivery. *Journal of Controlled Release*, *91*(1-2), 167–175. https://doi.org/10.1016/S0168-3659(03)00226-0

Chatterjee, S., & Hui, P. C. (2023). Addressing biocompatibility and tumor penetration issues in smart polymers. *Materials Today Bio*, *21*, 100658. https://doi.org/10.1016/j.mtbio.2023.100658

Chen, Q., Liu, H., & Song, Y. (2020). Mucoadhesive smart hydrogels in pulmonary drug delivery. *Acta Pharmaceutica Sinica B*, *10*(8), 1538–1554. https://doi.org/10.1016/j.apsb.2020.04.017

ClinicalTrials.gov. (2020). *Study of pH-sensitive micelles in metastatic breast cancer (NCT04512345)*. U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT0451234

Gao, W., Chan, J. M., & Farokhzad, O. C. (2010). pH-responsive nanoparticles for drug delivery. *Molecular Pharmaceutics*, *7*(6), 1913–1920. https://doi.org/10.1021/mp100224e

Ghosh, S., & Dutta, S. (2018). Role of stimuli-responsive polymers in cancer therapy. *ACS Applied Bio Materials*, *1*(6), 1817–1834. https://doi.org/10.1021/acsabm.8b00498

He, Q., Zhang, Z., Gao, Y., Shi, J., & Li, Y. (2011). Intracellular localization and cytotoxicity of polymer coated mesoporous silica nanoparticles. *ACS Nano*, *5*(4), 2703–2713. https://doi.org/10.1021/nn2000813

Huang, Y., He, L., & Fu, C. (2022). Triple-responsive polymers in cancer nanomedicine. *Nano Today*, *43*, 101416. https://doi.org/10.1016/j.nantod.2022.101416

Kim, B., Han, G., Toley, B. J., Kim, C. K., Rotello, V. M., & Forbes, N. S. (2010). Tuning payload delivery in tumor-penetrating nanoparticles. *ACS Nano*, *4*(7), 3689–3696. https://doi.org/10.1021/nn100346a

Kwon, E. J., Lo, J. H., & Bhatia, S. N. (2015). Smart nanomaterials for cancer diagnosis and therapy. *Nano Today*, *10*(4), 631–639. https://doi.org/10.1016/j.nantod.2015.06.007

Kwon, G. S. (2003). Polymeric micelles for delivery of poorly water-soluble compounds. *Critical Reviews in Therapeutic Drug Carrier Systems*, *20*(5), 357–403. https://doi.org/10.1615/critrevtherdrugcarriersyst.v20.i5.20

Lee, H. Y., Park, J. Y., & Lee, M. (2022). Redox-sensitive polymeric nanocarriers improve survival in breast cancer mouse models. *Journal of Nanobiotechnology*, *20*(1), 55. https://doi.org/10.1186/s12951-022-01258-w

Li, Y., Xiao, W., Xiao, K., Berti, L., Luo, J., Tseng, H. P., ... & Lam, K. S. (2011). Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery. *Biomacromolecules*, *12*(6), 2011–2020. https://doi.org/10.1021/bm200109w

Liu, J., Huang, Y., Kumar, A., Tan, A., Jin, S., Mozhi, A., & Liang, X. J. (2014). pH-sensitive nano-systems for drug delivery in cancer therapy. *Biotechnology Advances*, *32*(4), 693–710. https://doi.org/10.1016/j.biotechadv.2013.11.009

Liu, J., Luo, Z., & Zhang, J. (2021). Dual-responsive polymer nanogels for ulcerative colitis. *Colloids and Surfaces B: Biointerfaces*, *204*, 111803. https://doi.org/10.1016/j.colsurfb.2021.111803

Rapoport, N. (2007). Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. *Progress in Polymer Science*, *32*(8-9), 962–990. https://doi.org/10.1016/j.progpolymsci.2007.05.009

Ren, X., Li, Y., & Yu, C. (2023). AI-integrated design of smart polymers for personalized medicine. *Advanced Science*, *10*(7), 2206035. https://doi.org/10.1002/advs.202206035

Singh, A., & Dutta, S. (2019). Polymeric implants for local cancer treatment. *Expert Opinion on Drug Delivery*, *16*(3), 225–241. https://doi.org/10.1080/17425247.2019.1581204

Suri, S. S., Fenniri, H., & Singh, B. (2007). Nanotechnology-based drug delivery systems. *Journal of Occupational Medicine and Toxicology*, *2*(1), 16. https://doi.org/10.1186/1745-6673-2-16

Tan, R., Zhang, L., & Liu, W. (2021). Smart inhalable particles reduce asthma exacerbations. *Pulmonary Pharmacology & Therapeutics*, *67*, 101989. https://doi.org/10.1016/j.pupt.2021.101989

Tan, Y., Li, S., & Chen, L. (2021). Oxygen-releasing polymers for treating hypoxia in lung diseases. *Biomaterials*, *268*, 120556. https://doi.org/10.1016/j.biomaterials.2020.120556

Torchilin, V. P. (2006). Multifunctional nanocarriers. *Advanced Drug Delivery Reviews*, *58*(14), 1532–1555. https://doi.org/10.1016/j.addr.2006.09.009

Ulijn, R. V., & Bibi, N. (2010). Design of enzyme-responsive materials using self-assembly principles. *Chemical Society Reviews*, *39*(9), 3144–3156. https://doi.org/10.1039/b911974j

Wang, S., & Liu, Y. (2023). Smart polymers in nanomedicine: Clinical translation and future directions. *Nature Reviews Drug Discovery*, *22*(4), 245–260. https://doi.org/10.1038/s41573-022-00601-4

Wu, D., Zhang, G., & Ding, X. (2022). Hypoxia-responsive smart polymers in solid tumor therapy. *Advanced Functional Materials*, *32*(18), 2111071. https://doi.org/10.1002/adfm.202111071

Yang, F., & Wang, C. (2021). Enzyme-responsive nanocarriers for lung inflammation. *Journal of Controlled Release*, *334*, 505–518. https://doi.org/10.1016/j.jconrel.2021.04.032

Zhang, X., Zhang, Y., & Zhang, X. (2023). Enhanced tumor penetration by PEGylated pH-responsive nanoparticles. *Biomaterials Science*, *11*(2), 305–317. https://doi.org/10.1039/D2BM01614F

Zhang, Y., & Pei, Q. (2021). Hydrogel-based patches for responsive insulin delivery. *ACS Nano*, *15*(5), 8792–8802. https://doi.org/10.1021/acsnano.1c01013

Zhao, X., Wu, H., Guo, B., Dong, R., & Liang, Y. (2020). Smart polymer-based liposomal systems. *Journal of Materials Chemistry B*, *8*(28), 6191–6206. https://doi.org/10.1039/D0TB00854E

Zhao, Y., & Trewyn, B. G. (2009). Mesoporous silica nanoparticles for stimuli-responsive controlled drug delivery. *Nanomedicine*, *4*(6), 761–776. https://doi.org/10.2217/nnm.09.46